Company intelligence / Profile preview
Immunochina Pharmaceuticals
Beijing, Beijing, Chinaimmunochina.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Immunochina Pharmaceuticals (Imunopharm) is a leading Chinese clinical-stage biopharmaceutical company specializing in innovative gene and cell therapies—primarily CAR-T—for the treatment of malignant tumors. The company has presented positive clinical data at major international conferences such as ASCO and ASH. It holds seven China INDs for its pipeline products targeting both hematologic malignancies and solid tumors. Its lead product IM19 has received multiple IND approvals for relapsed/refractory B-cell acute lymphocytic leukemia and non-Hodgkin's lymphoma.
- Therapeutic areas
- OncologyImmunology
- Modalities
- CAR-T cell therapyGene therapyCell therapy
- Industry
- Biotech
02
Drug pipeline
23 assets22 more assets in the full pipeline.
03
Partnerships
EdigeneSimcere PharmaceuticalPeking University Third HospitalBeijing Cancer Hospital
Beyond the preview
Go deeper on Immunochina Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunochina Pharmaceuticals.